KRAS G12C Inhibitor

LY3537982

KRAS G12C Inhibitor

Peng SB, et al1; Kano Y, et al2; Janes MR, et al3; Ji J, et al4

Target
KRAS is the most common oncogene across all tumor types. KRAS G12C represents a KRAS mutation in patients with non-small cell lung cancer (14%), colorectal cancer (3%), and other solid tumors (1%-3%).4
Molecule
LY3537982 is a selective covalent inhibitor of KRAS G12C; in preclinical models, it demonstrates activity as monotherapy and in combination with other anticancer therapies. It has competitive pharmacokinetic properties supporting its advancement into clinical testing. LY3537982 has been shown in vitro to target a KRAS G12C mutation, thereby inhibiting mutant KRAS-dependent signaling.1
Clinical Development
LY3537982 is being studied in a clinical trial in patients with non-small cell lung cancer, colorectal cancer, or other advanced solid tumors.

References

  1. Peng SB, et al. Cancer Res. 2021;81(suppl 13):1259.
  2. Kano Y, et al. Nat Commun. 2019;10(1):224.
  3. Janes MR, et al. Cell. 2018;172(3):578-589.
  4. Ji J, et al. Onco Targets Ther. 2022;15:747-756.
Clinical Development
LY3537982 is being studied in a clinical trial in patients with non-small cell lung cancer, colorectal cancer, or other advanced solid tumors.

References

  1. Peng SB, et al. Cancer Res. 2021;81(suppl 13):1259.
  2. Kano Y, et al. Nat Commun. 2019;10(1):224.
  3. Janes MR, et al. Cell. 2018;172(3):578-589.
  4. Ji J, et al. Onco Targets Ther. 2022;15:747-756.

Need additional information or have a question:

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

DISCOVER OTHER MOLECULES

VEGF Receptor-2 Antagonist

Learn More

CDK4 & 6 Inhibitor

Learn More

RET Inhibitor

Learn More